CYTH RSI Chart
Last 7 days
-4.8%
Last 30 days
15.7%
Last 90 days
-20.4%
Trailing 12 Months
21.3%
Historical Charts for Stock Metrics
Year | Q1 | Q2 | Q3 | Q4 |
---|---|---|---|---|
2024 | 2.1M | 0 | 0 | 0 |
2023 | 2.4M | 2.2M | 2.2M | 2.1M |
2022 | 1.4M | 1.7M | 1.7M | 2.5M |
2021 | 1.0M | 1.2M | 1.6M | 1.5M |
2020 | 1.1M | 1.0M | 835.0K | 989.6K |
2019 | 1.0M | 957.9K | 1.0M | 1.0M |
2018 | 1.1M | 957.1K | 940.4K | 1.0M |
2017 | 1.5M | 1.6M | 1.6M | 1.2M |
2016 | 1.1M | 1.1M | 1.1M | 1.5M |
2015 | 1.2M | 1.4M | 1.2M | 950.5K |
2014 | 1.7M | 1.1M | 1.4M | 1.6M |
2013 | 1.2M | 1.7M | 1.8M | 1.7M |
2012 | 1.2M | 941.3K | 867.4K | 988.0K |
2011 | 853.0K | 912.6K | 972.2K | 1.0M |
2010 | 0 | 0 | 0 | 793.4K |
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
Feb 13, 2024 | sieger markus | acquired | - | - | 14,004 | - |
Feb 13, 2024 | shanahan william s | acquired | - | - | 8,466 | - |
Feb 13, 2024 | wong vivien | acquired | - | - | 6,330 | - |
Feb 13, 2024 | strattan ce rick | acquired | - | - | 6,963 | - |
Feb 13, 2024 | conkling william | acquired | - | - | 6,330 | - |
Feb 13, 2024 | ostronic francis patrick | acquired | - | - | 8,703 | - |
Feb 13, 2024 | toig randall m. | acquired | - | - | 7,516 | - |
Dec 27, 2023 | cross shawn | acquired | - | - | 72,606 | - |
Nov 28, 2023 | conkling william | acquired | - | - | 7,466 | - |
Nov 28, 2023 | wong vivien | acquired | - | - | 2,488 | - |
Which funds bought or sold CYTH recently?
View All DetailsDatesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
May 15, 2024 | STATE STREET CORP | added | 0.01 | -7,898 | 54,947 | -% |
May 15, 2024 | CITADEL ADVISORS LLC | added | 0.18 | -653 | 2,638 | -% |
May 15, 2024 | CITADEL ADVISORS LLC | sold off | -100 | -85,889 | - | -% |
May 15, 2024 | Royal Bank of Canada | unchanged | - | - | 1,000 | -% |
May 15, 2024 | Tower Research Capital LLC (TRC) | added | 12.11 | -186 | 9,149 | -% |
May 15, 2024 | Founders Fund V Management, LLC | unchanged | - | -96,142 | 668,184 | 61.12% |
May 15, 2024 | Steward Partners Investment Advisory, LLC | unchanged | - | -18.00 | 125 | -% |
May 15, 2024 | EPIQ Capital Group, LLC | new | - | 1,186,800 | 1,186,800 | 0.47% |
May 15, 2024 | Founders Fund VI Management, LLC | unchanged | - | -22,005 | 152,932 | 57.89% |
May 15, 2024 | BANK OF AMERICA CORP /DE/ | added | 92.86 | 16.00 | 38.00 | -% |
Unveiling Cyclo Therapeutics, Inc.'s Major ShareHolders
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Peers (Alternatives to Cyclo Therapeutics, Inc.)
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
JNJ | 372.2B | 85.6B | 9.67 | 4.35 | ||||
MRK | 332.3B | 61.4B | 144.1 | 5.41 | ||||
AMGN | 167.7B | 29.5B | 44.55 | 5.68 | ||||
PFE | 162.3B | 57.8B | 129.52 | 2.81 | ||||
GILD | 84.4B | 27.4B | 174.21 | 3.07 | ||||
TEVA | 18.4B | 16.0B | -37.29 | 1.15 | ||||
MID-CAP | ||||||||
ALKS | 4.1B | 1.7B | 9.41 | 2.37 | ||||
PRGO | 4.1B | 4.6B | -528.11 | 0.89 | ||||
BHC | 2.5B | 9.0B | -5.45 | 0.28 | ||||
AMPH | 2.1B | 676.2M | 13.75 | 3.14 | ||||
SMALL-CAP | ||||||||
TLRY | 1.5B | 743.2M | -4.35 | 2.06 | ||||
TXMD | 25.8M | 1.3M | -3.49 | 19.84 | ||||
ACRX | 18.4M | 89.6M | -1.29 | 0.19 | ||||
AGRX | 2.5M | 21.5M | -0.32 | 0.12 | ||||
ACOR | 633.5K | 115.7M | 0 | 0.01 |
Cyclo Therapeutics, Inc. News
Income Statement (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
Revenue | -80.3% | 202,450 | 1,030,109 | 495,477 | 414,402 | 152,411 | 1,174,082 | 452,167 | 649,842 | 194,904 | 360,301 | 450,490 | 373,618 | 358,133 | 381,912 | 72,319 | 209,594 | 325,734 | 227,363 | 285,914 | 273,095 | 220,826 |
Gross Profit | - | 190,627 | - | - | - | 142,215 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Costs and Expenses | -9.5% | 5,311,689 | 5,869,555 | 5,262,937 | 4,750,060 | 5,159,543 | 5,030,779 | 4,700,667 | 3,997,910 | 3,129,361 | 3,378,431 | 4,262,934 | 3,839,042 | 4,395,409 | 2,827,049 | 1,658,461 | 2,411,497 | 2,967,774 | 2,865,224 | 1,914,539 | 1,643,379 | 2,128,616 |
R&D Expenses | -31.3% | 2,845,483 | 4,144,336 | 3,469,067 | 3,170,199 | 3,398,167 | 3,184,948 | 2,856,160 | 1,874,383 | 1,084,052 | 1,414,401 | 1,837,720 | 2,643,544 | 3,258,115 | 1,236,651 | 1,086,753 | 1,713,435 | 2,059,606 | 1,798,047 | 941,539 | 786,811 | 1,342,763 |
EBITDA Margin | 5.6% | -9.04 | -9.57 | -8.66 | -8.59 | -7.27 | -6.25 | -7.99 | -7.76 | -9.43 | -9.25 | -9.05 | -9.89 | - | - | - | - | - | - | - | - | - |
Interest Expenses | 203.6% | 756 | 249 | 4,341 | 3,736 | 1,730 | - | - | - | - | 3,525 | - | -269 | 269 | 304 | 224 | - | - | - | - | - | - |
Income Taxes | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Earnings Before Taxes | 23.0% | -4,343,063 | -5,642,409 | -4,771,353 | -4,636,455 | -5,007,085 | -4,980,427 | -4,246,880 | -3,451,990 | -2,771,591 | -2,792,386 | -3,860,256 | -3,597,398 | -4,036,615 | -2,679,610 | -1,435,609 | -2,192,392 | -2,633,992 | -2,635,015 | -1,625,341 | -1,368,011 | -1,904,166 |
EBT Margin | 5.6% | -9.05 | -9.59 | -8.67 | -8.60 | -7.28 | -6.25 | -8.00 | -7.78 | -9.44 | -9.26 | -9.06 | -9.91 | - | - | - | - | - | - | - | - | - |
Net Income | 23.0% | -4,343,000 | -5,642,409 | -4,771,353 | -4,636,455 | -5,007,085 | -4,980,427 | -4,246,880 | -3,451,990 | -2,771,591 | -2,792,386 | -3,860,256 | -3,597,398 | -4,036,615 | -2,679,610 | -1,435,609 | -2,192,392 | -2,633,992 | -2,635,015 | -1,625,341 | -1,368,011 | -1,904,166 |
Net Income Margin | 5.6% | -9.05 | -9.59 | -8.67 | -8.60 | -7.28 | -6.25 | -8.00 | -7.78 | -9.44 | -9.26 | -9.06 | -9.91 | - | - | - | - | - | - | - | - | - |
Free Cashflow | -43.9% | -6,184,553 | -4,297,302 | -4,041,199 | -3,478,706 | -4,370,239 | -2,746,780 | -3,191,955 | -4,355,743 | -4,834,849 | -2,611,671 | -3,026,842 | -4,462,466 | - | - | - | - | - | - | - | - | - |
Balance Sheet | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
Assets | -45.9% | 7,164 | 13,248 | 5,597 | 4,643 | 4,097 | 4,215 | 8,488 | 11,842 | 15,924 | 19,521 | 11,097 | 14,243 | 18,141 | 14,188 | 4,132 | 2,262 | 2,286 | 4,113 | 5,862 | 7,591 | 1,905 |
Current Assets | -46.7% | 6,570 | 12,318 | 5,512 | 4,548 | 3,993 | 4,159 | 8,422 | 11,777 | 15,850 | 19,436 | 10,992 | 14,121 | 18,021 | 14,050 | 3,972 | 2,088 | 2,097 | 3,958 | 5,690 | 7,403 | 1,688 |
Cash Equivalents | -67.6% | 2,995 | 9,247 | 1,802 | 842 | 915 | 1,543 | 4,290 | 7,453 | 11,799 | 16,613 | 8,441 | 11,463 | 15,507 | 12,846 | 2,238 | 1,008 | 933 | 2,784 | 4,994 | 6,608 | 1,115 |
Inventory | -4.6% | 243 | 254 | 210 | 237 | 244 | 254 | 271 | 261 | 221 | 227 | 254 | 269 | 258 | 238 | 421 | 217 | 229 | 243 | 384 | 398 | 413 |
Net PPE | -36.5% | 24.00 | 38.00 | 41.00 | 46.00 | 50.00 | 55.00 | 60.00 | 55.00 | 59.00 | 60.00 | 64.00 | 68.00 | 50.00 | 54.00 | 57.00 | 60.00 | 61.00 | 14.00 | 16.00 | 17.00 | 18.00 |
Current Liabilities | -22.8% | 6,536 | 8,468 | 6,622 | 6,096 | 4,500 | 3,481 | 2,875 | 2,102 | 2,876 | 3,831 | 3,420 | 3,035 | 3,707 | 3,673 | 4,560 | 4,057 | 3,952 | 3,141 | 2,337 | 2,705 | 2,637 |
Long Term Debt | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 71.00 | 98.00 | - | - | - | - | - |
LT Debt, Current | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 87.00 | 61.00 | - | - | - | - | - |
LT Debt, Non Current | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 71.00 | 98.00 | - | - | - | - | - |
Shareholder's Equity | -87.2% | 610 | 4,757 | - | - | -438 | 735 | 5,612 | 9,740 | 13,048 | 15,672 | 7,627 | 11,126 | 14,322 | 10,452 | - | - | - | 936 | 3,483 | 4,840 | - |
Retained Earnings | -5.2% | -88,199 | -83,856 | -78,214 | -73,442 | -68,806 | -63,799 | -58,819 | -54,572 | -51,120 | -48,348 | -45,556 | -41,695 | -38,098 | -34,061 | -31,382 | -29,946 | -27,754 | -25,120 | -22,485 | -20,859 | -19,491 |
Additional Paid-In Capital | 0.2% | 88,807 | 88,611 | 77,160 | 71,957 | 68,367 | 64,533 | 64,431 | 64,311 | 64,167 | 64,020 | 53,183 | 52,821 | 52,419 | 44,514 | 30,841 | 28,012 | 26,044 | 26,056 | 25,956 | 25,688 | 18,701 |
Shares Outstanding | 0.2% | 28,614 | 28,556 | 19,365 | 15,308 | 10,054 | 8,482 | 8,428 | 8,418 | 8,412 | 8,404 | 6,041 | 6,368 | - | - | - | - | - | - | - | - | - |
Float | - | - | - | - | 17,226 | - | - | - | 14,693 | - | - | - | 76,509 | - | - | - | 11,147 | - | - | - | 25,510 | - |
Cashflow (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
Cashflow From Operations | -43.9% | -6,182 | -4,294 | -4,041 | -3,478 | -4,370 | -2,746 | -3,181 | -4,355 | -4,830 | -2,611 | -3,026 | -4,439 | -4,926 | -3,061 | -1,608 | -2,061 | -1,809 | -2,220 | -1,622 | -1,521 | -1,225 |
Share Based Compensation | - | 173 | - | 127 | 41.00 | 92.00 | 72.00 | 89.00 | 87.00 | 107 | 64.00 | 181 | - | 50.00 | - | - | - | - | - | - | - | 7.00 |
Cashflow From Investing | 100.0% | - | -2.42 | - | - | - | - | 18.00 | 11.00 | 9.00 | 10.00 | 7.00 | -5.66 | 3.00 | 13.00 | 7.00 | 7.00 | -41.01 | 10.00 | 9.00 | 9.00 | 8.00 |
Cashflow From Financing | -100.6% | -69.28 | 11,742 | 5,001 | 3,405 | 3,742 | - | - | - | 7.00 | 10,773 | -1.78 | 402 | 7,584 | 13,657 | 2,831 | - | - | - | - | 7,005 | 115 |
Condensed Consolidated Statements of Operations (Unaudited) - USD ($) | 3 Months Ended | |
---|---|---|
Mar. 31, 2024 | Mar. 31, 2023 | |
REVENUES | ||
Product sales | $ 202,450 | $ 152,411 |
Cost of products sold (exclusive of direct and indirect overhead and handling costs) | 11,823 | 10,196 |
GROSS PROFIT | 190,627 | 142,215 |
Costs and Expenses [Abstract] | ||
Personnel | 822,481 | 906,955 |
Research and development | 2,845,483 | 3,398,167 |
Repairs and maintenance | 2,363 | 1,252 |
Professional fees | 630,388 | 482,835 |
Office and other | 892,213 | 282,375 |
Board of Directors fees and costs | 104,398 | 72,125 |
Depreciation | 2,177 | 4,819 |
Freight and shipping | 373 | 819 |
Loss on disposal of equipment | 11,813 | 0 |
Total operating expenses | 5,311,689 | 5,149,347 |
LOSS FROM OPERATIONS | (5,121,062) | (5,007,132) |
Other Income, Nonoperating [Abstract] | ||
Investment and other income, net | 237,568 | 47 |
Investment and other income | 540,431 | 0 |
Total other income (expense), net | 777,999 | 47 |
LOSS BEFORE INCOME TAXES | (4,343,063) | (5,007,085) |
PROVISION FOR INCOME TAXES | 0 | 0 |
NET LOSS | $ (4,343,063) | $ (5,007,085) |
BASIC AND DILUTED NET LOSS PER COMMON SHARE (in dollars per share) | $ (0.15) | $ (0.46) |
WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING (in shares) | 28,585,228 | 11,003,588 |
Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($) | Mar. 31, 2024 | Dec. 31, 2023 |
---|---|---|
CURRENT ASSETS | ||
Cash and cash equivalents | $ 2,995,178 | $ 9,246,592 |
Accounts receivable, net of allowances of $0 and $10,272, respectively | 71,322 | 122,379 |
Inventory, net | 242,530 | 254,352 |
Prepaid insurance and services | 442,838 | 384,889 |
Prepaid clinical expenses | 2,818,204 | 2,310,045 |
Total current assets | 6,570,072 | 12,318,257 |
FURNITURE AND EQUIPMENT, NET | 24,342 | 38,332 |
RIGHT-OF-USE LEASE ASSET, NET | 569,476 | 890,949 |
TOTAL ASSETS | 7,163,890 | 13,247,538 |
Current portion of lease liability | 647,556 | 1,010,631 |
Accounts payable and accrued expenses | 5,888,813 | 7,457,416 |
Total current liabilities | 6,536,369 | 8,468,047 |
Lease liability, net of current portion | 17,507 | 22,484 |
Total long-term liabilities | 17,507 | 22,484 |
STOCKHOLDERS' EQUITY | ||
Preferred stock, par value $.0001 per share, 5,000,000 shares authorized, 0 outstanding | 0 | 0 |
Common stock, par value $.0001 per share, 250,000,000 shares authorized, 28,614,384 and 28,556,072 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively | 2,862 | 2,856 |
Additional paid-in capital | 88,806,896 | 88,610,832 |
Accumulated deficit | (88,199,744) | (83,856,681) |
Total stockholders' equity (deficit) | 610,014 | 4,757,007 |
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT) | $ 7,163,890 | $ 13,247,538 |
 | Mr. N. Scott Fine |
---|---|
 | https://cyclotherapeutics.com |
 | Pharmaceuticals |
 | 9 |